- Home
- IGC
IGC
IGC Pharma Inc.
as 07-26-2024 4:00pm EST
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | POTOMAC |
| Market Cap: | 32.5M | IPO Year: | N/A |
| Target Price: | $3.38 | AVG Volume (30 days): | 168.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $0.91 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,345,000 | Revenue Growth: | 47.64% |
| Revenue Growth (this year): | 5.06% | Revenue Growth (next year): | N/A |
Latest IGC Pharma Inc. News
IGC Breaking Stock News: Dive into IGC Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
Business Wire
17 days ago
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Business Wire
a month ago
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
Business Wire
a month ago
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
Business Wire
a month ago
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Business Wire
2 months ago
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
Business Wire
2 months ago
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
Business Wire
2 months ago
IGC Pharma to Attend BIO International Convention 2024
Compare IGC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IGC IGC Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.